Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2016 View overview page

3:18
Targeted therapies for CLL: new data and unanswered questions
Jennifer Brown • 3 Jun 2016
3:35
INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety results
Elias Jabbour • 3 Jun 2016
1:21
Checkmate 205: the use of nivolumab to treat relapsed Hodgkin lymphoma
Anas Younes • 3 Jun 2016
2:35
Embracing the use of social media at medical congresses
Joseph Mikhael
2:14
Key tips for using Twitter for hematologists
Michael Thompson • 3 Jun 2016
1:04
Highlights from ASCO 2016 for myeloproliferative neoplasms
Ruben Mesa • 3 Jun 2016
1:24
The management of transaminitis in patients receiving idelalisib
William Wierda • 3 Jun 2016
2:10
Why hematologists should use social media
Michael Thompson • 3 Jun 2016
2:18
Updates on PERSIST-1 trial of pacritinib for myelofibrosis
Ruben Mesa • 3 Jun 2016
0:58
Topics in multiple myeloma discussed at ASCO 2016
Sagar Lonial • 3 Jun 2016
1:57
Side effects of idelalisib in CLL and how to manage them
Jennifer Brown • 3 Jun 2016
2:24
Quality over quantity – a look at the ASH and ASCO social media networks
Michael Thompson • 3 Jun 2016
1:36
Features of high-risk multiple myeloma and how to treat it
Keith Stewart • 3 Jun 2016
1:13
ASCO 2016 highlights for multiple myeloma
Rafael Fonseca • 3 Jun 2016
2:00
Preliminary results of the AIM trial of ibrutinib and venetoclax in mantle cell lymphoma
Constantine Tam • 3 Jun 2016
1:34
The rising cost of drugs and how to address it
Bruce Johnson • 3 Jun 2016
The content of VJHemOnc is intended for healthcare professionals